Statements of Income
Subsequent Events
Bayer Links
Management Report
Subsequent Events
In April 2007 the Japanese Ministry of Health, Labor and Welfare (MHLW) approved the novel cholesterol-lowering agent ZETIA® (ezetimibe). ZETIA® will be co-marketed by Bayer Yakuhin Ltd. and Schering-Plough K.K. Japan. The drug is approved for use either as mono-therapy or co-administered with a statin, for further reduction of LDL (“bad”) cholesterol.
The co-marketing agreement regarding ZETIA® in Japan is part of Bayer’s strategic pharmaceuticals alliance with Schering-Plough, which was announced in 2004. Bayer’s primary care pharmaceutical products, such as the antibiotics Avelox® and Cipro®, the cardiovascular product Adalat® and also Levitra® are today marketed and distributed by Schering-Plough in the United States and Puerto Rico.
Please note that Bayer Schering Pharma AG, Germany* is not legally related to Schering-Plough Corporation, New Jersey, United States. The two companies have been totally independent of each other for many years.
The co-marketing agreement regarding ZETIA® in Japan is part of Bayer’s strategic pharmaceuticals alliance with Schering-Plough, which was announced in 2004. Bayer’s primary care pharmaceutical products, such as the antibiotics Avelox® and Cipro®, the cardiovascular product Adalat® and also Levitra® are today marketed and distributed by Schering-Plough in the United States and Puerto Rico.
Please note that Bayer Schering Pharma AG, Germany* is not legally related to Schering-Plough Corporation, New Jersey, United States. The two companies have been totally independent of each other for many years.
*
The names "Bayer Schering Pharma" or "Schering" as used in this publication always refer to Bayer Schering Pharma AG, Berlin, Germany, or its predecessor, Schering AG, Berlin, Germany, respectively.
Bookmark this page
E-mail this page
Advanced Search
